Sunrest Lifescience
- P/E
- 5.38
Key Fundamentals
SMEPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · TTM
- ROCE
- 23.20%
- Debt to Equity
- 0.85
- EPS (TTM)
- ₹6.60
- Book Value
- ₹47.60
- Market Cap
- —
- P/E (TTM)
- 5.38
- P/B
- 0.75
- ROE
- 15.20%
- Dividend Yield
- 0.00%
- EBITDA
- ₹12.70 Cr
- 52W High
- ₹54.00
- 52W Low
- ₹26.37
- Day Range
- ₹35.50 – ₹35.50
- Volume
- 1,600
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Sunrest Lifescience (this company) | ₹35.50 | 5.38 | ₹64 Cr | 0.75 | 0.00% | 15.20% | 23.20% | ₹19 Cr | ₹2 Cr |
| Median 8 companies | ₹1,587.70 | 37.20 | ₹1,25,337 Cr | 4.57 | 0.44% | 16.25% | 19.15% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Key Insights
Strengths
2- Stock is trading at 0.73 times its book value
- Debtor days have improved from 283 to 168 days.
Weaknesses
2- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 168 days.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 7 | 0 |
| Oscillators | Bearish | 2 | 7 | 0 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Bearish
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 47.18
- Neutral
- MACD (12,26,9)
- −0.49
- Bearish
- SMA (50)
- 37.94
- Bearish
- SMA (200)
- 39.39
- Bearish
As of
Growth Rate
From the financial statements below. 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 1Y | +111.40% |
|---|
Net profit
| 1Y | +296.04% |
|---|
Operating cash flow
| 1Y | Turned negative |
|---|
Operating margin· change in pp
| 1Y | +5.39 pp |
|---|
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2025 | ₹33.41 Cr |
|---|---|
| Mar 2026 | ₹70.63 Cr |
Net profit by year
| Mar 2025 | ₹2.02 Cr |
|---|---|
| Mar 2026 | ₹8.00 Cr |
Half-yearly Results
₹ Cr| Particulars | Sep 2024 | Sep 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 15.39 | 34.01 | 36.82 |
| Expenses | 14.48 | 31.56 | 30.07 |
| Operating Profit | 0.91 | 2.45 | 6.75 |
| OPM % | 5.91% | 7.2% | 18.33% |
| Other Income | 0 | 0 | 2.51 |
| Interest | 0.12 | 0.72 | 0.7 |
| Depreciation | 0.01 | 0.68 | 0.51 |
| PBT | 0.78 | 1.05 | 8.05 |
| Tax % | 24.36% | 37.14% | 18.51% |
| Net Profit | 0.58 | 0.66 | 6.57 |
| EPS (₹) | 1.35 | 0.79 | 7.88 |
Profit & Loss
₹ Cr| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 33.41 | 70.63 |
| Expenses | 30.38 | 60.42 |
| Operating Profit | 3.03 | 10.21 |
| OPM % | 9.07% | 14.46% |
| Other Income | 0 | 2.51 |
| Interest | 0.31 | 1.42 |
| Depreciation | 0.1 | 1.19 |
| PBT | 2.62 | 10.11 |
| Tax % | 23.28% | 20.87% |
| Net Profit | 2.02 | 8 |
| EPS (₹) | 4.68 | 9.6 |
| Div. Payout % | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity Capital | 4.29 | 4.29 |
| Reserves | 12.02 | 16.14 |
| Borrowings | 12.06 | 17.46 |
| Other Liabilities | 30.28 | 33.52 |
| Total Liabilities | 58.65 | 71.41 |
| Fixed Assets | 4.36 | 8.55 |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| Other Assets | 54.29 | 62.86 |
| Total Assets | 58.65 | 71.41 |
Cash Flow
₹ Cr| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating | 2.92 | −0.05 |
| Investing | −1.15 | −2.91 |
| Financing | −0.33 | 3.99 |
| Net Cash Flow | 1.45 | 1.03 |
| Free Cash Flow | 1.76 | −2.76 |
| CFO/EBITDA | 112 | 14 |
Ratios
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Debtor Days | 397 | 168 |
| Inventory Days | 175 | 141 |
| Days Payable | 417 | 173 |
| Cash Conversion Cycle | 155 | 135 |
| Working Capital Days | 228 | 156 |
| ROCE % | — | 23.22% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Sunrest Lifescience insights
58 extracted metrics across FY23–FY26.
Documents
- 9 Oct 2026
- 30 Sep 2026
- 11 Sep 2026
Frequently Asked Questions about Sunrest Lifescience
What does Sunrest Lifescience Ltd do?
Where is Sunrest Lifescience Ltd (SUNREST) listed?
Which sector does Sunrest Lifescience Ltd belong to?
What is the PE ratio of Sunrest Lifescience Ltd?
What is the 52-week high and low of Sunrest Lifescience Ltd?
What is the Return on Equity (ROE) of Sunrest Lifescience Ltd?
Company Information
Incorporated in 2017, Sunrest Lifescience Ltd trades in Health care and Cosmetics products
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUNREST.md for Sunrest Lifescience Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.